Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
Viking Therapeutics (VKTX) currently holds four phase 3 trials for its key drug, VK2735, which could potentially be worth a significant amount by 2028. The two subcutaneous (injectable) trials are already underway, with data expected in the second half of 2027. Meanwhile, the two oral phase 3 trials have just begun and are projected to provide data in 2028.
The oral trials have the potential to expand the drug's addressable market by offering a dual-formulation strategy. Viking Therapeutics' success will depend on the efficacy and tolerability of VK2735 compared to its competitors. Based on current data, if VK2735 manages to secure 10% of the projected sales of a similar drug, its peak sales could amount to approximately $7 billion.
However, due to the uncertainties surrounding the clinical trials, it is estimated that peak sales could be around $3.5 billion. With a conservative assumption of a 50% probability of success, Viking Therapeutics could have a market cap of $10.5 billion to $17.5 billion. At its current trading price, a $10,000 investment could potentially be worth up to $47,800 by 2028.
The Motley Fool's Stock Advisor services may provide further insights into potential investment opportunities.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
